SRX 246

Drug Profile

SRX 246

Alternative Names: API 246; SRX246

Latest Information Update: 16 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Azevan Pharmaceuticals
  • Class Heart failure therapies; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Impulse control disorders; Post-traumatic stress disorders
  • Phase I/II Behavioural disorders
  • Phase I Anxiety disorders

Most Recent Events

  • 03 Feb 2017 Phase-I clinical trials in Anxiety disorders (In volunteers) in USA (PO) (NCT02922166)
  • 27 Jan 2017 The National Institute of Mental Health plans a phase I trial in Healthy volunteers in USA (PO) (NCT03036397)
  • 01 Dec 2016 Phase-II clinical trials in Post-traumatic stress disorder in USA (PO) (NCT02733614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top